SUMMARY In a longitudinal study the relevance of the detection of low avidity antibodies to double stranded DNA (dsDNA) as measured by the polyethylene glycol (PEG) assay in patients with systemic lupus erythematosus (SLE) was evaluated. It was found that 35 patients positive in the PEG assay only-that is, having only low avidity anti-dsDNA in their circulation, had a mild course of their SLE with absence of renal involvement. The PEG assay had little predictive value but a high specificity (90-2%) for clinical exacerbations; furthermore, a change in avidity of antidsDNA in such patients was seldom observed. In 14 patients positive in both Farr and PEG assays-that is, with a relative preponderance of high avidity anti-dsDNA, there was a clear correlation between rises in Farr assay and major exacerbations, while the PEG assay on its own was not helpful in predicting disease manifestations; disease manifestations were often heralded by a change in the Farr/PEG ratio, with renal and cerebral exacerbations associated with the greatest increase in the Farr/PEG ratio (more than 10 times the previous value).
Systemic lupus erythematosus (SLE) is considered to be the prototype autoimmune disease, in which immune complexes mediate inflammatory processes, though the mechanism by which they do so remains uncertain.1-3 Antibodies to double stranded DNA (dsDNA) have been shown to be sensitive, though not specific markers for SLE.6 Different properties of the anti-dsDNA antibody (specificity, avidity, complement binding capacity, immunoglobulin subclass) have been related to the various clinical manifestations of SLE.7-10 The Farr assay is widely used for measurement of anti-dsDNA antibodies but detects mainly high avidity antibodies; the polyethylene glycol (PEG) assay, on the other hand, is thought to detect low avidity antibodies to dsDNA and uses a less powerful precipitation method, associations with autoimmune liver disease and myasthenia gravis and fair specificity for SLE; a longitudinal study showed a good correlation between Farr and PEG assays and clinical manifestations,'3 while a high Farr/PEG ratio (>5) was found to be associated with renal disease and a Farr/PEG ratio below five with cerebral disease in other studies.1116
We studied the clinical significance of the PEG assay in two groups of patients with SLE. In serum samples of group I patients anti-dsDNA was detectable only with the PEG assay, whereas in the serum samples of group II patients anti-dsDNA was detectable by both the Farr and PEG assays. Our results indicate a fairly benign course of SLE for group I patients and a low predictive value of changes in anti-dsDNA levels, measured by the PEG assay, for disease exacerbations. Group (320 U/ml) for antibodies to dsDNA in the PEG assay, but negative (<20 U/l) in the Farr assay. Their attending physicians were asked to obtain serum samples every two months and to provide clinical information through questionnaires or record investigation, or both. In this way 491 serum samples were obtained.
Group II consisted of 14 patients fulfilling at least four of the American Rheumatism Association criteria for SLE, whose sera were positive (320 U/ml) in both the Farr and PEG assays for antibodies to dsDNA; the same follow up procedure was used as for group I patients. In this group 89 serum samples were obtained. The incubation was carried out at 37°C for one hour, followed by a two hour incubation at 4°C. The mixture was then centrifuged for 15 minutes at 4000 rpm in a Hettich Rotanta/K centrifuge (2500 g). The radioactivity in 200 pLI of the supernatant was measured after addition of 10 ml of NE-260sp (New England Nuclear Corp, USA). A '0% binding' control, in which serum was omitted, was included in each experiment. Anti-DNA activity was expressed in U/ml instead of percentage binding, using the definition of Aarden et a120 for the Farr assay-that is, a sample contains one unit of anti-DNA if it binds 30% of 100 ng PM2-DNA under the conditions described above. A significant change in the PEG assay was arbitrarily defined as a change of 50% or more compared with the result obtained two months previously.
FARR ASSAY
The Farr assay was performed as described by Aarden et 
Discussion
Autoantibodies to dsDNA occur in most patients with SLE4 and, although rises in anti-dsDNA titres are associated with disease manifestationsl9 22 their definite role in the pathogenesis of SLE remains to be established. The Faff assay for anti-dsDNA measures antibodies with high avidity, whereas the PEG assay also measures low avidity antidsDNA.1' 12 The PEG assay has been little used owing to uncertainty about its clinical usefulness.
Early studies correlated low avidity anti-DNA with early and more severe disease manifestation in mice23 and renal involvement in man,24 but these findings were later contradicted.25 26 To determine the clinical significance of the PEG assay we followed up two groups of patients with SLE; one group, whose serum samples showed positive anti-dsDNA only by the PEG assay and a second group whose sera reacted positively in both Farr and PEG assays. Our results show that patients with SLE with anti-dsDNA only detectable by the PEG assay have a low incidence of disease manifestations with a complete absence of renal involvement; all patients were female and were relatively old when diagnosed as having SLE; the prevalence of other disease manifestations was lower than reported elsewhere, except for cerebral involvement, which was comparable with that of other groups of patients.17 27 Changes in anti-dsDNA levels measured by the PEG assay were not helpful in predicting clinical disease, in contrast with results obtained with the Farr assay'9 22; specificity on the other hand was high (90.2%). This means that small changes in anti-dsDNA levels detected by the PEG assay (less than 50%) are not associated with disease exacerbations; this is illustrated by the disease course of a patient shown in Fig. 2 .
The second part of our study concerned patients with SLE whose sera contained anti-dsDNA detected by both Farr and PEG assays. We found a close correlation between increases in the Farr/PEG ratio and major disease manifestations, which confirms previous findings of the predictive value of rising anti-dsDNA titres in the Farr assay19 22 dsDNA level of a female patient. The raised Farr/PEG ratio for both renal and cerebral disease exacerbations in this study seeminglv contrasts with previous findings,'F'6 which showed a Farr/PEG ratio above five to be specific for renal disease. In the current study, however, we looked at changes in the Farr/PEG ratio rather than at absolute values and therefore our findings of a rising ratio can be used as additional information for predicting SLE exacerbations next to the initial value of the Farr/ PEG ratio.
In conclusion, we showed that a subset of patients with SLE exists, which consists of older women with only low avidity anti-dsDNA, who experience less exacerbations and do not develop renal disease. In these patients the PEG assay is not a sensitive marker for disease activity; about 17% of these patients develop high avidity anti-dsDNA detectable by the Farr assay, when experiencing an exacerbation. Furthermore, we showed that in patients with SLE positive in both Farr and PEG assays the PEG assay is of little prognostic value, whereas the Farr assay can be used to predict major exacerbations. A 100% increase in the Farr/PEG ratio over a two month period heralds a major exacerbation of SLE, with renal and cerebral disease associated with the highest increases. 
